telisotuzumab
abbvie
['sclc', 'lcsm,(-blcsm)', 'telisotuzumab', ' vision', 'nsclc']
#asco22 update on telisotuzumab vedotin (teliso-v), a met-idc in met ihc+ nsclc. toxicities include edema (common with met inhibitors, often dose-limiting in my experience) and here, blurry vision and keratitis (low grade). #lcsm 
Director of Thoracic Oncology & Developmental Therapeutics @LombardiCancer, Associate Professor @Georgetown University #LCSM #HereWeGo #ITYSL He/Him